Oruka Therapeutics Inc (ORKA) Actualités

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody

Pharmacokinetic and safety data from healthy volunteers anticipated in the second half of 2025 On track to...

Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)

MENLO PARK, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a...

Form EFFECT - Notice of Effectiveness

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Oruka Therapeutics to Present at Piper Sandler’s 36th Annual Healthcare Conference

MENLO PARK, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a...

Form 8-K - Current report

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form S-8 - Securities to be offered to employees in employee benefit plans